文献速递前列腺癌

抗雄激素撤退后PSA反应:系统综述与荟萃分析

PSA response to antiandrogen withdrawal: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-18

该系统综述与荟萃分析纳入23项研究共1474例晚期前列腺癌患者,评估抗雄激素撤退(AAW)后的PSA反应。总体26%患者出现任何PSA下降,11%出现≥50%下降;第一代抗雄激素者反应率较高(30%任何下降,15%≥50%下降),而第二代抗雄激素和雄激素合成抑制剂反应率低。

要点

  • 约四分之一晚期前列腺癌患者抗雄激素撤退后出现PSA下降。
  • 第一代抗雄激素撤退后PSA反应率高于第二代及雄激素合成抑制剂。
  • 第二代抗雄激素和雄激素合成抑制剂撤退后PSA反应罕见。

核心结论

  • 约26%的晚期前列腺癌患者接受抗雄激素撤退后出现任何PSA下降,11%出现≥50%下降。
  • 第二代抗雄激素和雄激素合成抑制剂撤退后PSA反应不常见。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Cochrane和EMBASE截至2020年11月23日,纳入23项研究共1474例晚期前列腺癌患者。
  • 由两名评价者筛选文献并提取数据,采用随机效应和固定效应模型进行荟萃分析,并按抗雄激素类型进行亚组分析。

主要发现

  • 总体395例(26%,95%CI:20-32%)患者出现任何PSA下降,183例(11%,95%CI:6-16%)出现≥50%PSA下降。
  • 第一代抗雄激素组1212例中,30%(95%CI:23-38%)出现任何PSA下降,15%(95%CI:8-22%)出现≥50%下降。
  • 第二代抗雄激素组108例中,7%(95%CI:0-13%)出现任何PSA下降,1%(95%CI:0-5%)出现≥50%下降。
  • 雄激素合成抑制剂组154例中,26%(95%CI:19-33%)出现任何PSA下降,4%(95%CI:0-13%)出现≥50%下降。

临床怎么用

  • 对于接受第一代抗雄激素治疗的晚期前列腺癌患者,可考虑抗雄激素撤退以评估PSA反应。
  • 对于使用第二代抗雄激素或雄激素合成抑制剂的患者,抗雄激素撤退后PSA反应预期较低。

局限性

  • 需要进一步研究以理解不同类型抗雄激素之间PSA反应差异的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiandrogen withdrawal (AAW) response is the paradoxical decrease in prostate-specific antigen (PSA) following the withdrawal of antiandrogen in patients with advanced prostate cancer. Currently, the reported literature on the proportion of patients exhibiting AAW response and the differences in PSA response between the types of antiandrogens is unclear. METHODS: This review aimed to explore the PSA response to AAW and to identify if the response depends on the type of antiandrogens. A literature search was performed using databases PubMed, Cochrane and EMBASE with a cut-off date of 23rd of November 2020. Studies reporting on outcomes of AAW and prostate cancer were included. Studies were screened by two reviewers and relevant data extracted. Meta-analysis of outcomes was reported using random-effects and fixed-effects model. A subgroup analysis was performed for type of antiandrogen. RESULTS: From 450 studies, 23 were included with a total of 1474 patients with advanced prostate cancer were available for further analysis. Overall, 395 (26%) patients had any reduction in PSA levels (95% CI: 20-32%) and 183 (11%) patients had a ≥50% reduction in PSA levels (95% CI: 6-16%). Among the 1212 patients on first-generation antiandrogens, 30% (95% CI: 23-38%) had any PSA decline with 15% patients having a ≥50% PSA decline (95% CI: 8-22%). In contrast, among the 108 patients on second-generation antiandrogens, 7% (95% CI: 0-13%) had any PSA decline and only 1% (95% CI: 0-5%) had a ≥50% PSA decline. Also, among the 154 patients on androgen synthesis inhibitors, 26% (95% CI: 19-33%) had any PSA decline and only 4% (95% CI: 0-13%) had a ≥50% PSA decline. CONCLUSIONS: One-fourth of patients treated with AAW show a PSA response. However, PSA response to AAW is uncommon with second-generation antiandrogens and androgen synthesis inhibitors. Further research is required to understand the differences in response between the types of antiandrogen.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Soo A, O'Callaghan ME, Kopsaftis T, et al. PSA response to antiandrogen withdrawal: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 33603235. doi:10.1038/s41391-021-00337-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。